目的观察强肾片联合龙鹿胶囊治疗多囊卵巢综合征(PCOS)伴胰岛素抵抗(IR)患者的临床疗效。方法将124例PCOS伴IR肾阳虚患者随机分为治疗组73例(给予强肾片及龙鹿胶囊),对照组51例(口服二甲双胍治疗),疗程6个月;两组患者于治疗前后测定内脂素、体重指数(BMI)、空腹血糖(FPG)、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR),评价排卵恢复率及临床疗效。结果治疗后两组内脂素、BMI、FINS、HOMA-IR水平均较治疗前降低(P<0.01),而FPG治疗前后差异无统计学意义(P>0.05);两组治疗后上述指标比较差异均无统计学意义(P>0.05);治疗组排卵恢复率、临床疗效与对照组比较差异无统计学意义(P>0.05)。结论强肾片联合龙鹿胶囊能有效改善PCOS伴IR患者胰岛素抵抗及排卵情况,且疗效与二甲双胍相当。 Objective To observe the clinical effects of Qiangshen Tablet combined with Longlu Capsule in patients with PCOS and insulin resistance (IR). Methods A total of 124 PCOS patients with IR deficiency of kidney-yang were randomly divided into treatment group (given Qiangshen Tablets and Longlu Capsule) and control group (oral metformin treatment group) for 73 months. The treatment course was 6 months. Before and after treatment The contents of visfatin, body mass index (BMI), fasting blood glucose (FPG), fasting insulin (FINS) and insulin resistance index (HOMA-IR) were measured to evaluate the ovulation recovery rate and clinical efficacy. Results The levels of visfatin, BMI, FINS and HOMA-IR in the two groups after treatment were lower than those before treatment (P <0.01), but there was no significant difference between the two groups before and after FPG treatment (P> 0.05) There was no significant difference between the two groups (P> 0.05). There was no significant difference in ovulation recovery rate and clinical curative effect between the treatment group and the control group (P> 0.05). Conclusions Qiangshen tablets combined with Longlu capsule can effectively improve insulin resistance and ovulation in PCOS patients with IR, and the curative effect is comparable with metformin.